Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Xeloda and Radiotherapy for Bone Metastases
NCT00192777Phase 2Unknown
- Sponsor
- Rambam Health Care Campus
- Start
- Nov 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in bone metastases, sponsored by Rambam Health Care Campus. Primary endpoint: Frequency of pain relief for the proposed regimen at 3 months. Status: unknown.
02
Drugs
capecitabine
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT00192777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192777.